PDCD1 and lung carcinoma: Indeed, in a recent in vivo study using an anti-PD-1 therapy-resistant mouse lung cancer cell line, suppression of type I IFN expression was associated with anti-PD-1 therapy resistance due to reduced MHC-I expression, but tumors became responsive to anti PD-1 therapy after XRT (66).